Consequences of New Approach to Chemical Stability Tests to Active Pharmaceutical Ingredients (original) (raw)

Abstract

There is a great need of broaden look on stability tests of active pharmaceutical ingredients (APIs) in comparison with current requirements contained in pharmacopeia. By usage of many modern analytical methods the conception of monitoring the changes of APIs during initial stage of their exposure to harmful factors has been developed. New knowledge must be acquired in terms of identification of each degradation products, especially volatile ones. Further research as toxicology prediction during in silico studies of determined and identified degradation products is necessary. In silico methods are known as computational toxicology or computer-assisted technologies which are used for predicting toxicology of pharmaceutical substances such as impurities or degradation products. This is a specialized software and databases intended to calculate probability of genotoxicity or mutagenicity of these substances through a chemical structure-based screening process and algorithm specific to ...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (27)

  1. Alsante, K. M., Huynh-Ba, K. C., Baertschi, S. W., Reed, R. A., Landis, M. S., Furness, S., et al. (2014). Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: safety considerations of impurities in pharmaceutical products and surveying the impurity landscape. AAPS PharmSciTech. 15, 237-251. doi: 10.1208/s12249-013-0061-z
  2. Baek, I. H., Kim, J. S., Ha, E. S., Choo, G. H., Cho, W., Hwang, S. J., et al. (2014). Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose. Int. J. Biol. Macromol. 67, 53-57. doi: 10.1016/j.ijbiomac.2014.03.006
  3. Brittain, H. G., Bogdanowich, S. J., Bugay, D. E., DeVincentis, J., Lewen, G., and Newman, A. W. (1991). Physical characterization of pharmaceutical solids. Pharm. Res. 8, 963-973. doi: 10.1023/A:1015888520352
  4. Carstensen, J. T. (1999). Drug stability: principles and practices, revised and expanded. Drugs Pharm. Sci. 92, 68-68.
  5. Chieng, N., Rades, T., and Aaltonen, J. (2011). An overview of recent studies on the analysis of pharmaceutical polymorphs. J. Pharm. Biomed. Anal. 55, 618-644. doi: 10.1016/j.jpba.2010.12.020
  6. Dow, L. K., Hansen, M. M., Pack, B. W., Page, T. J., and Baertschi, S. W. (2013). The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product. J. Pharm. Sci. 102, 1404-1418. doi: 10.1002/jps.23462
  7. EMA (2012). CHMP, Guideline on Stability Testing for Applications for Variations to a Marketing Authorization, London, UK. Available at: http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC5 00164972.pdf EMEA (2004). Committee for Medicinal Products for Human Use (CHMP), Guideline on the Limits of Genotoxic Impurities, CPMP/SWP/5199/02, London, UK. Available at: http://www.ema.europa.eu/docs/en\_GB/document\_library/ Scientific_guideline/2009/09/WC500002903.pdf (accessed June 23, 2004).
  8. EMEA (2009). Note for Guidance on the Use of Near Infrared Spectroscopy by the Pharmaceutical Industry and the Data Requirements for New Submissions and Variations, EMEA/CVMP/961/01. Available at: http://www.ema.europa.eu/do cs/en_GB/document_library/Scientific_guideline/2009/09/WC500003331.pdf European Pharmacopoeia (2015). European Pharmacopoeia Online, 8th Edn, Strasbourg: EDQM.
  9. FDA (2003). PAT-A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance (Draft Guideline). Available at: http://www.fda.gov/downlo ads/Drugs/Guidances/ucm070305.pdf
  10. Giordani, A., Kobel, W., and Gally, H. U. (2011). Overall impact of the regulatory requirements for genotoxic impurities on the drug development process. Eur. J. Pharm. Sci. 43, 1-15. doi: 10.1016/j.ejps.2011.03.004
  11. Glass, B. D., Novák, C., and Brown, M. E. (2004). The thermal and photostability of solid pharmaceuticals. J. Therm. Anal. Calorim. 77, 1013-1036. doi: 10.1016/j.jpba.2015.01.012
  12. Görög, S. (2015). Identification in drug quality control and drug research. Trends Anal. Chem. 69, 114-122. doi: 10.1016/j.trac.2014.11.020
  13. Huynh-Ba, K. (ed.) (2008). Handbook of Stability Testing in Pharmaceutical Development: Regulations, Methodologies, and Best Practices. New York, NY: Springer Science & Business Media.
  14. ICH M7 (2014). ICH M7 -Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. Available at: http://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/Guidelines/ Multidisciplinary/M7/M7_Step_4.pdf ICH Q10 (2008). ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q10: Pharmaceutical Quality System, ICH, Geneva, Switzerland. Available at: http://www.ich.org/fileadmin/Public\_Web\_Site/ ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf ICH Q1A (1993). (R) Stability Testing of New Drug Substances and Products, International Conference on Harmonisation, Szwajcaria, Geneve. Available at: http://www.pharma.gally.ch/ich/q1a038095en.pdf http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/ Q1A_R2__Guideline.pdf ICH Q1A (2003). (R2) STABILITY TESTING of New Drug Substances and Products, International Conference on Harmonisation, Szwajcaria, Geneva. Available at: http://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/Guidelines/ Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf ICH Q3A (1994). Impurities in New Drug Substances. Tripartite International Conference on Harmonization Guideline Q3A, Geneve. Available at: http://www.ich.org/fileadmin/Public\_Web\_Site/ICH\_Products/Guidelines/ Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf ICH Q3B (2000). (R). Draft revised guidance on impurities in new drug products. Fed. Regist. 65, 44791-44797.
  15. ICH Q8 (2009). ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q8 (R2): Pharmaceutical Development, ICH, Geneva, Switzerland. Available at: http://www.ich.org/ fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/ Q8_R2_Guideline.pdf ICH Q9 (2005). ICH of Technical Requirements for Registration of Pharmaceuticals for Human Use, Topic Q9: Quality Risk Management, ICH, Geneva, Switzerland. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm073511.pdf
  16. Jamrógiewicz, M., and Ciesielski, A. (2015). Application of vibrational spectroscopy, thermal analyses and X-Ray diffraction in the rapid evaluation of the stability in solid-state of ranitidine, famotidine and cimetidine. J. Pharm. Biomed. Anal. 107, 236-243. doi: 10.1016/j.jpba.2015.01.012
  17. Jamrógiewicz, M., and Wielgomas, B. (2013). Detection of some volatile degradation products released during photoexposition of ranitidine in a solid state. J. Pharm. Biomed. Anal. 76, 177-182. doi: 10.1016/j.jpba.2012. 12.019
  18. Liu, J., Zhou, W., You, T., Li, F., Wang, E., and Dong, S. (1996). Detection of hydrazine, methylhydrazine, and isoniazid by capillary electrophoresis with a palladium-modified microdisk array electrode. Anal. Chem. 68, 3350-3353. doi: 10.1021/ac9604696
  19. McGovern, T., and Jacobson-Kram, D. (2006). Regulation of genotoxic and carcinogenic impurities in drug substances and products. TrAC Trends Anal. Chem. 25, 790-795. doi: 10.1016/j.taap.2012.03.001
  20. Olsen, B. A., and Larew, L. A. (2005). "Comparative stress stability studies for rapid evaluation of manufacturing changes or materials from multiple sources, " in Pharmaceutical Stress Testing: Predicting Drug Degradation, ed. S. W. Baertschi (Boca Raton, FL: CRC Press).
  21. Paradowska, K., and Wawer, I. (2014). Solid-state NMR in the analysis of drugs and naturally occurring materials. J. Pharm. Biomed. Anal. 93, 27-42. doi: 10.1016/j.jpba.2013.09.032
  22. Reddy, A. V. B., Jaafar, J., Umar, K., Majid, Z. A., Aris, A. B., Talib, J., et al. (2015). Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review. J. Sep. Sci. 38, 764-779. doi: 10.1002/jssc.201401143
  23. Reynolds, D. W., Facchine, K. L., Mullaney, J. F., Alsante, K. M., Hatajik, T. D., and Motto, M. G. (2002). Available guidance and best practices for conducting forced degradation studies. Pharm. Technol. 26, 48-56.
  24. Sun, M., Bai, L., Terfloth, G. J., Liu, D. Q., and Kord, A. S. (2010). Matrix deactivation: a general approach to improve stability of unstable and reactive pharmaceutical genotoxic impurities for trace analysis. J. Pharm. Biomed. Anal. 52, 30-36. doi: 10.1016/j.jpba.2009.11.027
  25. Waterman, K. C., and Adami, R. C. (2005). Accelerated aging: prediction of chemical stability of pharmaceuticals. Int. J. Pharm. 293, 101-125. doi: 10.1016/j.ijpharm.2004.12.013
  26. WHO (2012). Guidelines on Submission of Documentation for a Multisource (Generic) Finished Pharmaceutical Product for the WHO Prequalification of Medicines Programme: Quality Par, Annex 4, 2012. Available at: http://www.who.int/medicines/areas/quality\_safety/quality\_assurance/expert\_ committee/TRS-970-pdf1.pdf
  27. Yoshioka, S., and Aso, Y. (2007). Correlations between molecular mobility and chemical stability during storage of amorphous pharmaceuticals. J. Pharm. Sci. 96, 960-981. doi: 10.1002/jps.20926